Browse the evidence

Even after bariatric surgery, patients may not lose the expected amount of weight or may experience weight regain.

Understand that bariatric surgery may not guarantee weight loss success and additional support may be needed.

Over 700 million people worldwide suffer from obesity, which is directly or indirectly responsible for about 7% of all deaths.

Healthcare practitioners should recognize the widespread impact of obesity on public health.

Bariatric surgery is recommended for the treatment of type 2 diabetes in extreme cases.

Consider bariatric surgery for patients with severe diabetes who do not respond to other treatments.

Adipositas is influenced by environmental factors and genetic variants.

Understanding the dual influence of genetics and environment can guide obesity treatment strategies.

The current care for people with obesity in Germany is inadequate and relies on non-reimbursed services.

Practitioners should advocate for better reimbursement policies to improve obesity care.

The metabolic phenotype of the people of Bangladesh is different from Caucasians.

Understanding these differences is crucial for effective obesity management strategies.

Pharmacological treatments, particularly GLP-1 agonists, have shown promising results but are limited by lack of cost coverage.

Practitioners should be aware of the potential benefits of GLP-1 agonists while considering the financial implications for patients.

Obesity threatens to affect 30% of the world's population by 2030.

Health professionals should be aware of the rising obesity rates and their implications.

Orlistat's peak concentration stayed below 5 ng/mL, indicating minimal systemic absorption.

The low systemic absorption suggests a reduced risk of systemic side effects from orlistat.

Barriers to treatment for obesity-related hypertension include obesity stigma, limited access to healthcare, and adherence problems.

Addressing stigma and improving access to care are crucial for effective management of obesity-related hypertension.

The prevalence of obesity has increased four-fold over the four preceding decades, with concomitantly rising rates of hypertension.

Healthcare providers should be aware of the significant rise in obesity and hypertension prevalence.

Sub-chronic administration of 0839 and 0833 reduced food intake and body weight in DIO mice and rats.

These compounds may help in managing weight in populations with diet-induced obesity.

No significant differences in efficacy and safety of the drugs were found between age groups.

Efficacy and safety of these drugs appear consistent, regardless of age.

Tirzepatide has a favorable safety profile but requires further investigation.

Practitioners should consider tirzepatide as a treatment option while monitoring for adverse reactions.

Ambulatory blood pressure monitoring strengthens the association between blood pressure control and cardiovascular outcomes.

Utilizing ambulatory BP monitoring may improve cardiovascular risk assessment in patients treated with GLP-1RA.

Amylin receptor activators may have an adverse effect profile more favorable than that of GLP-1 receptor activators.

Amylin receptor activators may be a safer alternative to GLP-1 receptor activators for patients.

Grip strength declined by 38% following semaglutide treatment.

Monitoring grip strength may be important in patients receiving GLP-1RA therapy to assess muscle function.

Key therapeutic areas include innovative approaches for monogenic disorders, incretin mimetics, dual receptor agonists, microbiome analysis, and improved behavioural interventions.

Practitioners should consider these therapeutic areas for advancing treatment options.

Rates of obesity are projected to continue to increase, with severe obesity expected to be the most common body mass index category for women in the coming decade.

Practitioners should be aware of the increasing prevalence of obesity among women and its implications for health.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is very common in individuals with type 2 diabetes.

Healthcare providers should be aware of the high prevalence of MASLD in their diabetic patients.

The etiology of obesity is multifactorial, and long-term weight maintenance remains challenging.

Interventions for obesity must consider the multifactorial nature of the condition.

Adverse effects of tirzepatide are most often mild and well tolerated, with no significant impact on patients’ quality of life.

Tirzepatide may be a safe option for patients concerned about side effects.

Dual agonists provide additive and potentially synergistic metabolic benefits through complementary receptor activation.

Practitioners may explore the use of dual agonists for enhanced metabolic outcomes in patients.

Obesity treatment could generate a social return on investment of $3.81 per dollar nationally and $8.57 from states’ perspective.

Investing in obesity treatment can yield significant economic returns for states and the nation.